Kairos Pharma, Ltd. (NYSE American: KAPA) announced that its academic partner, Cedars-Sinai Medical Center, received $600,000 in funding from the Department of Defense Lung Cancer Research Program. This grant is specifically allocated to advance the development of ENV205.
ENV205 is a groundbreaking new drug designed to treat chemotherapy drug resistance and cachexia, a severe muscle-wasting condition affecting cancer patients. The funding will accelerate Kairos Pharma’s research efforts to develop this first-in-class therapy.
The therapy aims to reverse chemotherapy drug resistance, counteract muscle loss, improve strength, and enhance the effectiveness of existing cancer treatments. This non-dilutive funding underscores the scientific team's excellence and supports the progression of this promising new therapy toward clinical trials.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.